# MagnetisMM-6 (NCT05623020)

> A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05623020
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Pfizer
- Conditions: Multiple Myeloma
- Interventions: Elranatamab; Daratumumab; Lenalidomide; Dexamethasone; Bortezomib
- Enrollment: 1060
- Primary outcome: Part 1 Dose Limiting Toxicity
- Primary outcome: Part 2: Progression free survival per IMWG
- Primary outcome: Part 2: Minimal Residual Disease negative CR rate

## Commentary we found

- YouTube: 10
- X threads: 8
- Podcasts: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=magnetismm-6-nct05623020

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05623020", "email": "<work email>"}; the inbox owner confirms by the emailed link.